Beta Drugs H1 FY27: revenue up 29%, profit after tax up about 44%
BETA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 18.1 pts more than Nifty Microcap 250 and 17.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Beta Drugs reported H1 FY27 consolidated revenue from operations of INR 263.04 crore, up 29.2% from INR 203.6 crore. Earnings before interest, tax, depreciation and amortization rose about 30% to INR 61 crore. Profit after tax attributable to Beta Drugs rose to INR 34.3 crore from INR 23.9 crore. The corresponding margin edged up to 23.18% from 23.08%. Management targets FY27 revenue above INR 535 crore. The review conclusion was unmodified.
Positive: strong revenue and profit growth, slightly better margins and net cash support sentiment, though results depend on a stronger H2.